XALKORI PASS Physician Survey

• Research type

  Research Study

• Full title

  A cross-sectional study to evaluate the effectiveness of XALKORI Therapeutic Management Guide among physicians prescribing XALKORI in Europe.

• IRAS ID

  188842

• Contact name

  Huang Kui ,

• Contact email

  kui.huang@pfizer.com

• Sponsor organisation

  Pfizer

• Duration of Study in the UK

  2 years, 0 months, 30 days

• Research summary

  The objective of this study is to evaluate the effectiveness of the XALKORI Therapeutic Management Guide(TMG) implemented to mitigate the risks of visual disorders, QTc prolongation, hepatotoxicity, neutropenia and leukopenia, bradycardia, and (ILD)/pneumonitis in 10 countries in the European Union. The study will assess whether the Prescribers received, read, understood, and utilized the XALKORI TMG.

• REC name

  N/A

• REC reference

  N/A